07 February 2025
07 February 2025
Several FDA-approved drugs exist for treating alcohol use disorder (AUD), but they are seldom prescribed in general practice.
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from Eli Lilly.
The UK-based drugmaker reported a 21% increase in annual revenues, reaching £43bn ($54.1bn) in 2024.
Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU.
The asset purchase agreement between the two companies is valued at $3.12m.
Henlius could earn up to $131.6m, including an upfront payment of $33m.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
